Trial Profile
A Study of Augmentation With LY2216684 for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Edivoxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 27 Sep 2016 Results of pooled analysis from 4 adjunctive treatment trials and 1 monotherapy trial (n=2561) published in the Journal of Clinical Psychiatry.
- 19 Nov 2010 Results presented at the 10th International Forum on Mood and Anxiety Disorders
- 05 Mar 2010 Actual patient number (227) added as reported by ClinicalTrials.gov.